JW (Cayman) Therapeutics Co. Ltd (2126.HK) HKSE
1.92
+0.01(+0.52%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.92
+0.01(+0.52%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
281
First IPO Date
November 03, 2020
| Name | Title | Pay | Year Born |
| Feng Tian | CEO & Executive Director | 39,381 | 1978 |
| Min Liu | Chief Executive Officer & Executive Chairman | 2.05M | 1973 |
| Yiping Li | Co-Founder & Director | 6.49M | 1964 |
| Ka Man Ng | Company Secretary | 0 | 1978 |
| Jihua Qin | Vice President and Head of Marketing & Medical Affairs | 0 | 1980 |
| Zhen Xia | Head of Clinical Science Department | 0 | 1980 |
| Chunan Chen | Senior Vice President | 0 | 1974 |
| Mark J. Gilbert | Senior Advisor & Acting Chief Medical Officer | 0 | 1961 |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.